Ubrogepant is the generic name for Qulipta [1].
What is Ubrogepant used for?
Ubrogepant is a medication used to treat migraine headaches [1]. It is a type of drug known as a calcitonin gene-related peptide (CGRP) receptor antagonist [2].
How does Ubrogepant work?
Ubrogepant works by blocking the action of CGRP, a molecule that is thought to play a role in migraine pain [2]. By inhibiting CGRP, the medication can help reduce inflammation and blood vessel dilation that contribute to migraines [3].
When did Qulipta (Ubrogepant) receive FDA approval?
Qulipta, with the active ingredient ubrogepant, was approved by the U.S. Food and Drug Administration (FDA) in December 2019 [1].
What is the difference between Ubrogepant and other migraine treatments?
Ubrogepant is an acute treatment for migraines, meaning it is taken when a migraine starts to relieve symptoms. This differs from preventive migraine medications, which are taken regularly to reduce the frequency and severity of migraines. Ubrogepant is a CGRP receptor antagonist, a newer class of migraine medications compared to older options like triptans [2].
Where can I find information about Ubrogepant patents?
DrugPatentWatch.com provides comprehensive data on drug patents, including those related to ubrogepant. You can find detailed patent information and track patent expirations on their site [4].
What are the potential side effects of Ubrogepant?
Common side effects associated with ubrogepant may include nausea and fatigue [1]. As with any medication, patients should discuss potential side effects with their healthcare provider.
Sources:
[1] https://www.drugpatentwatch.com/drugs/ubrogreppant
[2] https://www.drugpatentwatch.com/class/cgrp-receptor-antagonists
[3] https://www.drugpatentwatch.com/drugs/ubrogeppant
[4] https://www.drugpatentwatch.com/